Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.
Johnson & Johnson (NYSE:JNJ ) 45th Annual TD Cowen Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Call Participants Josh Jennings - TD Cowen Josh Jennings Good morning. We are moving down the medical device track even further on Day Two of the TD Cowen 45th Annual Healthcare Conference.
Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, March 4.
Johnson & Johnson (JNJ) reachead $167.28 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
Generating passive income is a core aspect of my financial strategy. My goal is to eventually produce enough recurring investment income to cover my basic living expenses.
It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.